In addition, despite their CD69 expression, activated eosinophils in severe COVID-19 patients displayed lower levels of CD11a, CD63, and CD66b compared to the CD69+ eosinophils from patients with moderate COVID-19. This evidence concerns the gene CEACAM8 and COVID-19.